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losses, and informal care. Specific parameters to be entered by users are the preva-
lence of the mutation, treatment costs, specificity/sensitivity and cost of the test, 
survival data and the incidence of AEs. ConClusions: The proposed global model 
for the economic evaluation of targeted treatments using companion diagnostics in 
advanced/metastatic cancer treatment can, with minimal input, quickly generate 
cost-effectiveness analyses of targeted cancer treatment.
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objeCtives: To inform decision makers who seek extension of Universal Mass 
Vaccination (UMV) about the most optimal allocation of funds across multiple pre-
ventative interventions or vaccines. To account for decision makers preferences using 
MCDA. Methods: A multi cohort markov model was developed to assess clinical and 
economic consequences of vaccine preventable diseases in Japan. Disease incidence 
rates, direct medical costs and QoL data were obtained from local sources. Payer 
perspective only was considered. Optimization module utilizing linear programming 
was developed to maximize outcome of interest which serve as an objective function 
subject to budget and intervention coverage constraints. A working version of the 
model can be found at http: //www. digitalho. com/models/a/portfolio/index. html. 
The model was initially developed in Excel and then automatically transformed into 
a JavaScript application to allow for an online access. One way sensitivity analyses 
was conducted to parametric unceranity. Results: Model results indicate that the 
optimal mix of interventions depends primarily on the objective function. Various 
single objective functions or a combination of multiple weighted objectives lead to 
different mix of interventions. When prevention of death is as an objective function 
then pneumococcal and rotavirus vaccines are chosen. ConClusions: The proposed 
web based model is a complementary addition to the conventional cost-effectiveness 
assessment for preventative interventions. This model helps to understand sequence 
of introduction of prevantative interventions and expected health and economic 
outcomes over time. The use of MCDA framework helps users to define specfic health 
objectives to be used in optimisation module. The web based modeling solution pro-
vides a widespread access to an easy to use tool that can by used by authorities, 
academia and non-modeling professionals.
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objeCtives: For the evaluation of the potential cost-effectiveness of an early 
experimental therapy, we calibrated an existing micro-simulation model for radio-
therapy planning in lung cancer using pilot data. Methods: We used an exter-
nally validated micro-simulation model, build using Real World Evidence data. 
The model contained four clinical states from alive to death, with intermediate 
states ‘local recurrence’ and ‘metastasis’, with 5 transitions. Based on individual 
and time-dependent hazard rates, patients move through the model according to 
their combination of patient characteristics and random variation. For the experi-
mental dosis-escalation therapy we had limited pilot study data, which included 
overall survival and a number of baseline characteristics. The distribution of patient 
features in the cohort of the micro-simulation model was adjusted so that the simu-
lated patients had the same baseline characteristics as the patients that received 
experimental therapy. Alternative radiotherapy strategies affected 5 transitions in 
the model, quantified by 5 hazard ratios (HRs). Subsequently, HRs for experimental 
radiotherapy compared to current radiotherapy were calibrated until they were 
able to satisfactorily reproduce the survival curve of the pilot data. The best fitting 
sets of HRs were selected based on the least Sum of Squared Errors (SSE) of the 
model predictions and the survival curve of the experimental therapy on three 
time points. Results: The best fitting set HRs resulted in a SSE of 0,005 based on 
prediction errors at 1,2 and 3-year survival. Although 33 out of 1000 sets produced 
predictions with less than 5% prediction error, hazard ratios varied strongly within 
and over the different sets. ConClusions: By using calibration, we obtained a 
micro-simulation model that is suitable for the evaluation of new treatments in 
the absence of empirical data. The model will be used for cost-effectiveness analy-
ses, where the variation in hazard ratios within sets will be evaluated in scenario 
analyses.
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objeCtives: HTAs require information on costs and outcomes as well as the 
uncertainty around them for making reimbursement decisions. Uncertainty 
around costs and effects (outcome uncertainty) can be substantial and increas-
ingly so at more distal time points. However, the uncertainty surrounding the 
decision to adopt or reject a technology based on cost-effectiveness (decision 
uncertainty) evolves over time in a different manner. In this analysis, we intend 
to illustrate that increased outcome uncertainty need not result in increased 
decision uncertainty and that both may evolve over time differently. Methods: 
A previously published lifetime Markov model, built from UK health care perspec-
tive, was used in the analysis. The model compared the cost-effectiveness (CE) of 
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objeCtives: The term “fuzzy logic” was introduced in 1965 by LAZadeh. Compared 
to traditional logic, fuzzy logic variables may have a truth value in degree. Fuzzy 
logic has been applied to many fields, from economic analysis, to artificial intel-
ligence. However it has not been applied so far to pharmacoeconomics. We present a 
model of pharmacoeconomic decision based on fuzzy logic (Fuzzy Economic Review 
2001; 6 (2): 51-73) and applied to the selection of ranibizumab-aflibercept in treating 
AMD. Methods: According to a decision analysis model based on fuzzy logic four 
fuzzy variables that affect the choice of treatment are defined: treatment success 
(expressed as a probability), cost of success, cost of failure (expressed as inverses), 
and other conditions about the cost (negotiation, handling of drugs...). Based on 
the value of these fuzzy variables, three linguistic variables (High, Medium, Low) 
are defined to expressing convenience of choice. The combination of the three pos-
sible values for each of the variables gives us 81 possible decision rules, so that the 
(HHHH) would be the most favorable option and (LLLL) the more unfavorable. So 
a new fuzzy variable called “ranking” is established for classifying these options 
with 7 possible values (Very-unfavorable, unfavorable, slightly-unfavorable, neutral, 
slightly-favorable, favorable, very-favorable). The value of the fuzzy variables for 
ranibizumab and aflibercept were established based on pivotal clinical trials at 52 
weeks cited by the EMEA. Results: The matrices obtained for ranibizumab was 
(0.29,3. 55 10-4, -1.36 10-4 0.7), and aflibercept (0.269,7. 4 10-4 -2.59 10-4 0.3). These 
matrices correspond to decision rules (HLLM) and (HMML) and correspond to a 
ranking of “neutral” and “slightly-favorable”. ConClusions: It possible to apply 
methods of “fuzzy logic” to pharmacoeconomic studies to select the most favorable 
treatment. According to model, AMD treatment, with aflibercept would be a slightly 
more favorable option than ranibizumab.
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objeCtives: To use historical influenza incidence time series data to develop a 
predictive model using time series analysis methods to forecast expected num-
ber of reported influenza cases. bACKGRound: Influenza is a common disease 
associated with high mortality. Low vaccination rates motivate health officials to 
predict outbreaks and intervene accordingly. A predictive model would facilitate in 
deciding whether an apparent excess of cases represents an outbreak or a random 
variation. Methods: Google Flu Trend project data from 2003 to 2014 was used to 
construct this predictive model. The influenza time series data clearly had a sea-
sonal variation to it so a seasonally fit model using seasonal indicators, a seasonally 
fit model using trigonometric functions, and a multiplicative seasonal autoregres-
sive integrated moving average (SARIMA) model were considered. Fifty-two weeks 
of data from the time series were withheld from the model fitting process so as 
to evaluate the predictive capability of the selected model using mean absolute 
percentage error (MAPE). The Akaike’s Information Criterion (AIC) goodness of fit 
measure was used to select the model that fit the data the best (lower the bet-
ter). Results: The SARIMA model provided the best fit for the data with an AIC of 
6361.7. The seasonally fit model using seasonal indicators had an AIC of 8473.9 and 
the seasonally fit model using trigonometric functions had an AIC of 8438.2. The 
SARIMA model MAPE for the predicted 52 weeks was 87.5%. The forecasted values 
were within the 95% confidence band of the actual ending 52 week data, though at 
the high end of the band. ConClusions: The SARIMA model was an appropriate 
predictor for flu cases in 2013-4. The data used to construct the model included flu 
epidemics so removing these time periods would result in a model more appropri-
ate for non-epidemic periods.
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objeCtives: With the development of high priced new targeted treatment for can-
cer, there is a need to know as soon as possible if these treatments are likely to 
be cost-effective. The objective of this study was to develop a model with global 
parameters to estimate the cost-effectiveness of targeted treatments using compan-
ion diagnostics in advanced/metastatic cancer treatment. Methods: The model 
was developed to take into account parameters usually considered in conventional 
economic models in cancer (treatment costs, costs of cancer care, target population 
characteristics, survival data, utilities, disutilities and costs associated with adverse 
events (AEs), etc.), and also parameters specific to the companion diagnostic itself 
(mutation prevalence, test specificity and sensitivity, and cost). The model had to 
allow performing cost-utility analyses from both a Health Ministry and a societal 
perspective and for most common cancers (lung, breast, colorectal, prostate, cer-
vical/endometrial, bladder, and non-Hodgkin’s lymphoma). Results: The global 
model comprises a decision tree and a lifetime Markov model. The decision tree 
takes into account the sensitivity and specificity and cost of the companion diag-
nosis, and the prevalence of the biomarker/mutation in the eligible population. 
The Markov model with monthly cycles includes the following 3 health states: 
progression-free, progressive disease and death. Intrisic parameters of the model 
comprise the mean characteristics of the target population, utilities associated 
with health states, disutilities and costs associated with AEs, and costs associated 
with drug administration, cancer care, end-of-life care, follow-up visits, productivity 
